EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms

Jérémy Ariey-Bonnet, Raphael Berges, Marie-Pierre Montero, Baptiste Mouysset, Patricia Piris, Kevin Muller, Guillaume Pinna, Tim W Failes, Greg M Arndt, Philippe Morando, Nathalie Baeza-Kallee, Carole Colin und 9 weitere

eBioMedicine · 2023-09 · 95 · 104752

DOI: 10.1016/j.ebiom.2023.104752 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eBioMedicine, 2023-09. Verfasst von Jérémy Ariey-Bonnet und 20 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille Université, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), In…. Hauptthemen laut MEDLINE: Glioblastoma, Antineoplastic Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Commission Marie Sklodowska-Curie Actions, European Research Council, Fondation ARC pour la Recherche sur le Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pharmacological synergisms are an attractive anticancer strategy. However, with more than 5000 approved-drugs and compounds in clinical development, identifying synergistic treatments represents a major challenge. METHODS: High-throughput screening was combined with target deconvolution and functional genomics to reveal targetable vulnerabilities in glioblastoma. The role of the top gene hit was investigated by RNA interference, transcriptomics and immunohistochemistry in glioblastoma patient samples. Drug combination screen using a custom-made library of 88 compounds in association with six inhibitors of the identified glioblastoma vulnerabilities was performed to unveil pharmacological synergisms. Glioblastoma 3D spheroid, organotypic ex vivo and syngeneic orthotopic mouse models were used to validate synergistic treatments. FINDINGS: Nine targetable vulnerabilities were identified in glioblastoma and the top gene hit RRM1 was validated as an independent prognostic factor. The associations of CHK1/MEK and AURKA/BET inhibitors were identified as the most potent amongst 528 tested pairwise drug combinations and their efficacy was validated in 3D spheroid models. The high synergism of AURKA/BET dual inhibition was confirmed in ex vivo and in vivo glioblastoma models, without detectable toxicity. INTERPRETATION: Our work provides strong pre-clinical evidence of the efficacy of AURKA/BET inhibitor combination in glioblastoma and opens new therapeutic avenues for this unmet medical need. Besides, we established the proof-of-concept of a stepwise approach aiming at exploiting drug poly-pharmacology to unveil druggable cancer vulnerabilities and to fast-track the identification of synergistic combinations against refractory cancers. FUNDING: This study was funded by institutional grants and charities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaAntineoplastic AgentsAnimalsMiceAurora Kinase ADrug SynergismCell Line, TumorDrug Combinations

Stichwörter der Autor:innen

Cancer vulnerabilitiesDrug combination screeningGlioblastomaPharmacological synergismsTarget deconvolution

Substanzen

Aurora Kinase AAntineoplastic AgentsDrug Combinations

Autor:innen und Institutionen

  • Aix Marseille Université, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Paoli Calmettes, Centre de Recherche en Cancérologie de Marseil…
  • Aix Marseille Université, CNRS, UMR 7051, INP, Inst Neurophysiopathol, Marseille, France.
  • Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, University Paris-Sud, Université Paris-Saclay, Gif-sur-Yvette F-91198, France.
  • Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia; ACRF Drug Discovery Centre for Childhood Cancer, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney,…
  • Aix-Marseille University, Assistance Publique-Hopitaux de Marseille, Centre Hospitalo-Universitaire Timone, Service de Neuro-Oncologie, Marseille, France.
  • Aix Marseille Université, CNRS, UMR 7051, INP, Inst Neurophysiopathol, Marseille, France; Aix-Marseille University, Assistance Publique-Hopitaux de Marseille, Centre Hospitalo-Universitaire Timone, Service de Neuro-Onco…

Förderung

  • European Commission Marie Sklodowska-Curie Actions
  • European Research Council
  • Fondation ARC pour la Recherche sur le Cancer
  • Canceropôle PACA
  • Institut National Du Cancer
  • Aix-Marseille Université

Zitieren

APA

Ariey-Bonnet, J., Berges, R., Montero, M. P., Mouysset, B., Piris, P., Muller, K., Pinna, G., Failes, T. W., Arndt, G. M., Morando, P., Baeza-Kallee, N., Colin, C., Chinot, O., Braguer, D., Morelli, X., André, N., Carré, M., Tabouret, E., Figarella-Branger, D., …, & Pasquier, E. (2023). Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms. eBioMedicine, 95, 104752. https://doi.org/10.1016/j.ebiom.2023.104752

Vancouver

Ariey-Bonnet J, Berges R, Montero MP, Mouysset B, Piris P, Muller K, et al. Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms. eBioMedicine. 2023;95:104752. doi:10.1016/j.ebiom.2023.104752

BibTeX
@article{ArieyBonnet2023,
  author = {Ariey-Bonnet, Jérémy and Berges, Raphael and Montero, Marie-Pierre and Mouysset, Baptiste and Piris, Patricia and Muller, Kevin and Pinna, Guillaume and Failes, Tim W and Arndt, Greg M and Morando, Philippe and Baeza-Kallee, Nathalie and Colin, Carole and Chinot, Olivier and Braguer, Diane and Morelli, Xavier and André, Nicolas and Carré, Manon and Tabouret, Emeline and Figarella-Branger, Dominique and Le Grand, Marion and Pasquier, Eddy},
  title = {Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms},
  journal = {eBioMedicine},
  year = {2023},
  volume = {95},
  pages = {104752},
  doi = {10.1016/j.ebiom.2023.104752}
}
Kostenlos starten →